Nicholas Haft
Founder at Delix Therapeutics, Inc.
Net worth: 302 913 $ as of 2024-04-29
Profile
Nicholas Haft is the founder of Delix Therapeutics, Inc. He is currently the Director at Arcos Ventures SPV LLC.
Previously, he served as the Independent Director at Finch Therapeutics Group, Inc. from 2020 to 2023.
He completed his undergraduate degree at The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-09 | 135,229 ( 8.42% ) | 302 913 $ | 2024-04-29 |
Nicholas Haft active positions
| Companies | Position | Start |
|---|---|---|
Delix Therapeutics, Inc.
 Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Founder | - |
| Arcos Ventures SPV LLC | Chief Executive Officer | 2015-03-31 |
Former positions of Nicholas Haft
| Companies | Position | End |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Director/Board Member | 2023-06-22 |
Training of Nicholas Haft
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private companies | 2 |
|---|---|
| Arcos Ventures SPV LLC | |
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Health Technology |
- Stock Market
- Insiders
- Nicholas Haft
